Hisao Higo

VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene‐driven non‐small‐cell lung cancers

Hiromi Watanabe, Eiki Ichihara, Hiroe Kayatani et al. · Cancer Science · 2021 · 55 citations · Full text

Medicine, Oncology, Pharmacology +17

MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib

Kiichiro Ninomiya, Kadoaki Ohashi, Go Makimoto et al. · Scientific Reports · 2018 · 47 citations · Full text

Medicine, Oncology, Pharmacology +17

Chemoradiotherapy for locally advanced lung cancer patients with interstitial lung abnormalities

Hisao Higo, Toshio Kubo, Satoko Makimoto et al. · Japanese Journal of Clinical Oncology · 2019 · 31 citations

Medicine, Oncology, Radiology +14

Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High Tumor Mutation Burden

Go Makimoto, Kadoaki Ohashi, Shuta Tomida et al. · Journal of Thoracic Oncology · 2019 · 30 citations · Full text

Medicine, Oncology, Pharmacology +17

CD8+ T-cell Responses Are Boosted by Dual PD-1/VEGFR2 Blockade after EGFR Inhibition in <i>Egfr</i> -Mutant Lung Cancer

Kazuya Nishii, Kadoaki Ohashi, Shuta Tomida et al. · Cancer Immunology Research · 2022 · 25 citations

Medicine, Immunology, Oncology +17